Galapagos NV announced that it developed GLPG1790, a novel candidate drug to treat breast cancer. GLPG1790 has shown high activity against breast tumors that are triple-negative, for which the absence of estrogen (ER), progesterone (PR) or HER2 receptors affects the prognosis for recovery, and no targeted therapeutic options are currently available. ..... "We are pleased to have developed a targeted approach towards triple-negative breast cancer. Targeted approaches in oncology typically show good efficacy and less toxicity than chemotherapy." http://www.leidenbiosciencepark.nl/news/news_item/t/galapagos_discovers_novel_candidate_drug_to_treat_breast_cancer Laten we hopen dat er eens iets beschikbaar komt voor deze groep voor wie momenteel geen minder intensieve behandeling is dan chemotherapie!